View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
August 3, 2009

Gen-Probe Broadens Intellectual Property Portfolio For Automated Nucleic Acid Testing

Patents relate to automated sample preparation and target nucleic acid amplification

By CBR Staff Writer

The US and European patent authorities have granted seven additional patents to Gen-Probe. It extend the company’s intellectual property estate related to automated instrument systems for nucleic acid testing (NAT).

The newly granted patents relate to automated sample preparation and target nucleic acid amplification, as well as closed-tube sampling. The patents complement an extensive portfolio of 65 patents previously granted to Gen-Probe, that relate to automated instrument systems for nucleic acid testing.

Bill Bowen, senior vice president and general counsel of Gen-Probe, said: These important new patents extend an already strong intellectual property estate surrounding automated instrumentation for molecular diagnostics, and further acknowledge the pioneering work our R&D team has done on behalf of our customers.

Content from our partners
Scan and deliver
GenAI cybersecurity: "A super-human analyst, with a brain the size of a planet."
Cloud, AI, and cyber security – highlights from DTX Manchester

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.